Last updated: July 29, 2026
What is the 3:17-cv-13151 litigation status and procedural posture in Bracco Diagnostics v. Maia Pharmaceuticals?
Answer: Not provided by the case caption. A procedural posture and status analysis requires docket events (e.g., motion to dismiss outcomes, claim construction dates, trial scheduling orders, dispositive rulings, and final disposition).
What court filings define the scope of the dispute (complaint, amended complaint, answer)?
No complaint details are included in the input. A scope definition requires:
- asserted patent numbers and application/patent family,
- accused products (drug/device/kit, dosage form, and label),
- counts pleaded (infringement, inducement, willful infringement, declaratory judgment),
- jurisdictional basis (e.g., Hatch-Waxman/Paragraph IV or other IP basis),
- requested remedies.
Did the case end in settlement, consent judgment, dismissal, or judgment?
No disposition information is included. A finality assessment requires:
- termination date and manner of termination,
- whether there is a consent judgment or stipulated final order,
- whether there is a license, covenant-not-to-sue, or entry-forbidden settlement.
Which patents did Bracco Diagnostics assert against Maia Pharmaceuticals in 3:17-cv-13151?
Answer: Not available from the caption alone.
Which patent claims were targeted and what infringement theories were pleaded?
A claim-level infringement summary requires:
- asserted claims (independent/dependent),
- claim chart themes (composition, method of use, formulation, manufacturing),
- doctrine of equivalents theories,
- inducement/contributory infringement allegations,
- willful infringement allegations and the basis for them.
What validity defenses did Maia raise (anticipation, obviousness, indefiniteness, enablement, written description)?
A validity analysis requires:
- invalidity assertions tied to specific prior art,
- whether Maia sought early invalidity rulings,
- expert report and Daubert issues (if any).
What claim construction issues drove the litigation in Bracco Diagnostics v. Maia (3:17-cv-13151)?
Answer: Not provided in the input.
What did the court construe for key terms (and how did it affect infringement/validity)?
A construction-driven analysis needs:
- Markman order date and the construed terms,
- “plain meaning” vs. construction outcomes,
- how construed terms map to accused product attributes.
Were there summary judgment rulings after claim construction?
Summary judgment outcomes require:
- the specific motions granted/denied,
- the legal standard applied,
- whether infringement or invalidity was resolved on a complete-record motion.
What does the docket show about remedies sought and potential exposure (injunction, damages, attorneys’ fees)?
Answer: Not available from the caption alone.
Did Bracco seek a permanent injunction or specify design-around risks?
In IP cases, remedies hinge on:
- whether an injunction request survived to merits,
- whether an equitable factor record exists,
- product launch timing and irreparable harm arguments.
What damages period and theory were pleaded (past damages, reasonable royalty, enhanced damages)?
A damages exposure analysis requires:
- date ranges tied to patent grant and notice,
- willfulness enhancement allegations,
- royalty model (if pleaded).
How does this litigation connect to FDA submissions, Orange Book listings, or Paragraph IV challenges (if applicable)?
Answer: Not determinable from the caption alone.
Was the case tied to an ANDA/505(b)(2) filing or a PIV challenge?
A Hatch-Waxman connection is not inferable without:
- FDA applicant names,
- ANDA/BLA/505(b)(2) numbers,
- Orange Book patents asserted,
- notice letter dates and details.
What regulatory pathway could be affected if the case involved drug product exclusivity?
Regulatory timing impact requires:
- the product category (small molecule, biologic, radiopharmaceutical),
- whether exclusivity was patent-based, data-based, or both,
- any settlement tied to launch dates.
What settlement terms are disclosed in 3:17-cv-13151, and what are the practical launch consequences?
Answer: Not available from the caption alone.
Did the parties enter into a covenant-not-to-sue or license agreement?
Launch consequences depend on:
- product scope in the settlement,
- permitted sales until a date,
- payment amount and allocation (if any),
- exclusivity or design-around constraints.
Did the settlement include stipulations on infringement/validity or only entry timing?
A practical analysis requires:
- whether parties stipulated to infringement,
- whether invalidity was waived,
- whether the settlement created future estoppel positions.
How strong is Bracco’s patent estate relative to Maia’s attack in this case (infringement vs. validity balance)?
Answer: Not computable from the provided input.
What was the evidence record (experts, testing, lab data, internal documents)?
An IP “strength” score depends on:
- technical evidence presented for each asserted element,
- reliability of testing,
- credibility findings and whether Daubert motions were granted.
What were the most critical legal vulnerabilities identified (if any)?
Legal vulnerabilities require:
- court holdings on invalidity,
- claim scope narrowing due to construction,
- pleading deficiencies dismissed.
What generic entry risks or biosimilar risks exist stemming from this litigation?
Answer: Not available without knowing the drug/product, patents asserted, and outcome.
If Maia was an FDA applicant, what launch entry date risk remains?
Risk depends on:
- whether patents were invalidated or found not infringed,
- whether settlement allows earlier entry,
- whether other Orange Book patents remain in force.
What design-around approaches were discussed in the record?
Design-around analysis needs:
- court or expert discussion of alternatives,
- whether Maia’s product differed in critical parameters,
- whether those differences would avoid infringement under construed claims.
Key Takeaways
- A litigation summary and analysis for Bracco Diagnostics Inc. v. Maia Pharmaceuticals, Inc. (3:17-cv-13151) cannot be produced from the caption alone without docket-specific substantive facts.
- A usable business assessment requires asserted patent numbers, accused products, pleaded claims, claim construction outcomes, dispositive rulings, and the final disposition or settlement terms.
- No determinations on exclusivity timing, patent strength, entry risk, or regulatory pathway impact are possible from the provided information.
FAQs
- What filings show which patents and claims were asserted in Bracco Diagnostics v. Maia Pharmaceuticals (3:17-cv-13151)?
- What Markman/claim-construction rulings changed the infringement analysis in this case?
- Did the court issue summary judgment on infringement or invalidity in 3:17-cv-13151?
- Was the lawsuit tied to an ANDA/Paragraph IV notice, and what FDA submission was involved?
- What settlement terms governed launch timing or allowed sales while patents remained at issue?
References
No sources were provided or cited because no docket or substantive case record details are included in the input.
